More than 900 vaccines are currently under investigation worldwide, according to data presented by the Argentine Chamber of Medicinal Specialties (CAEMe). This figure was highlighted during the Vaccination Week in the Americas, a period marked by accelerated transformation in immunization driven by latest technologies and advances in artificial intelligence.
Nearly half of these vaccine candidates aim to prevent diseases that currently lack preventive tools. Notable targets include HIV, tuberculosis, malaria and sexually transmitted infections such as gonorrhea and chlamydia. Researchers are too developing vaccines against Streptococcus A, herpes, hepatitis C, enterotoxigenic Escherichia coli, norovirus—which causes diarrheal illness—and cytomegalovirus, a particular concern during pregnancy due to its potential to cause congenital abnormalities.
The development of new immunogens is progressing rapidly, fueled by technological innovation. Flexible technological platforms now enable the creation of new vaccines in less time and with greater precision. The use of interchangeable common platforms has reduced processes that once took years to mere months, allowing for more agile responses to emerging threats.
Messenger RNA (mRNA) vaccines represent one of the clearest examples of this technological leap. Their success during the COVID-19 pandemic demonstrated how decades of research in omics technologies, artificial intelligence, and nanotechnology enabled record-breaking development timelines. Pharmaceutical nanotechnology proved essential in protecting the genetic material and ensuring its delivery to target cells.
This breakthrough opened a new era in vaccine and advanced therapy development, with applications extending beyond infectious diseases to include cancer treatment and other chronic conditions. The convergence of nanotechnology and molecular biology is laying the foundation for more precise and effective therapies, with the potential to transform medicine in the coming years.
Despite these advances, significant challenges remain in global equity and access to vaccines. As complex diseases emerge at increasing speeds, traditional methods are being re-evaluated to meet evolving public health needs.
